文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

低密度脂蛋白胆固醇(LDL-C)状态对他汀类药物治疗的糖尿病患者冠状动脉钙评分升高与斑块成分体积进展之间关联的影响:采用系列冠状动脉CTA进行评估

The effect of LDL-C status on the association between increased coronary artery calcium score and compositional plaque volume progression in statins-treated diabetic patients: evaluated using serial coronary CTAs.

作者信息

Shi Rui, Gao Yue, Shen Li-Ling, Shi Ke, Wang Jin, Jiang Li, Li Yuan, Yang Zhi-Gang

机构信息

Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China.

出版信息

Cardiovasc Diabetol. 2022 Jun 30;21(1):121. doi: 10.1186/s12933-022-01556-y.


DOI:10.1186/s12933-022-01556-y
PMID:35773708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9248151/
Abstract

BACKGROUND: In statins-treated diabetic mellitus (DM) patients, longitudinal coronary CTA (CCTA) evidence is scarce regarding the relationship between coronary Agatston artery calcification scores (CACs) and coronary plaque progression. This study was designed to investigate whether the association between CACs progression and compositional plaque volumes (PVs) progression differed between follow-up low-density lipoprotein cholesterol (LDL-C) controlled and uncontrolled groups in statins-treated DM patients. METHODS: From January 2015 to June 2021, 208 patients who submitted serial clinically indicated CCTAs in our hospital were included in this study. Participants were further subdivided into LDL-C controlled (n = 75) and LDL-C uncontrolled (n = 133) groups according to whether the LDL-C reached the treatment goals at follow-up. Baseline and follow-up CCTA image datasets were quantified analysis at per-patient and per-plaque levels. The annual change of total PV (TPV), calcific PV(CPV), non-calcific PV (NCPV), low-density non-calcific PV (LD-NCPV), and CACs were assessed and further compared according to follow-up LDL-C status. The effect of CACs progression on the annual change of componential PVs was evaluated according to follow-up LDL-C status at both per-patient and per-plaque levels. RESULTS: The annual change of CACs was positively associated with the annual change of TPV (β = 0.43 and 0.61, both p < 0.001), CPV (β = 0.23 and β = 0.19, p < 0.001 and p = 0.004, respectively), NCPV (β = 0.20 and β = 0.42, p < 0.001 and p = 0.006, respectively), and LD-NCPV (β = 0.08 and 0.13, p < 0.001 and p = 0.001, respectively) both on per-patients and per-plaque levels. LDL-C status had no effect on the annual change of TPV, CPV, NCPV, and LD-NCPV (all p > 0.05). After adjusting for confounding factors, on the per-patient level, the increase in CACs was independently associated with annual change of TPV (β = 0.650 and 0.378, respectively, both p < 0.001), CPV (β = 0.169 and 0.232, respectively, p = 0.007 and p < 0.001), NCPV (β = 0.469 and 0.144, respectively, both p = 0.001), and LD-NCPV (β = 0.082 and 0.086, respectively, p = 0.004 and p = 0.006) in LDL-C controlled and LDL-C uncontrolled group. On the per-plaque level, the increase in CACs was independently associated with the annual change of NCPV and LD-NCPV in LDL-C uncontrolled patient (β = 0.188 and 0.106, p < 0.001), but not in LDL-C controlled group (β = 0.268 and 0.056, p = 0.085 and 0.08). CONCLUSIONS: The increase of CACs in statins-treated DM patients indicates the progression of compositional PVs. From a per-plaque perspective, there might be increased instability of individual plaques concomitant with CACs increase in LDL-C uncontrolled patients.

摘要

背景:在接受他汀类药物治疗的糖尿病(DM)患者中,关于冠状动脉阿加斯顿动脉钙化评分(CACs)与冠状动脉斑块进展之间的关系,纵向冠状动脉CT血管造影(CCTA)证据较少。本研究旨在调查在接受他汀类药物治疗的DM患者中,随访低密度脂蛋白胆固醇(LDL-C)控制组和未控制组之间,CACs进展与斑块成分体积(PVs)进展之间的关联是否存在差异。 方法:2015年1月至2021年6月,纳入在我院接受系列临床指征CCTA检查的208例患者。根据随访时LDL-C是否达到治疗目标,将参与者进一步分为LDL-C控制组(n = 75)和LDL-C未控制组(n = 133)。对每位患者和每个斑块水平的基线和随访CCTA图像数据集进行定量分析。评估总PV(TPV)、钙化PV(CPV)、非钙化PV(NCPV)、低密度非钙化PV(LD-NCPV)和CACs的年度变化,并根据随访LDL-C状态进行进一步比较。在每位患者和每个斑块水平上,根据随访LDL-C状态评估CACs进展对各成分PV年度变化的影响。 结果:在每位患者和每个斑块水平上,CACs的年度变化与TPV的年度变化呈正相关(β分别为0.43和0.61,均p < 0.001)、CPV的年度变化(β分别为0.23和β为0.19,p < 0.001和p = 0.004)、NCPV的年度变化(β分别为0.20和β为0.42,p < 0.001和p = 0.006)以及LD-NCPV的年度变化(β分别为0.08和0.13,p < 0.001和p = 0.001)。LDL-C状态对TPV、CPV、NCPV和LD-NCPV的年度变化无影响(所有p > 0.05)。在调整混杂因素后,在每位患者水平上,LDL-C控制组和LDL-C未控制组中,CACs的增加分别与TPV的年度变化(β分别为0.650和0.378,均p < 0.001)、CPV的年度变化(β分别为0.169和0.232,p = 0.007和p < 0.001)、NCPV的年度变化(β分别为0.469和0.144,均p = 0.001)以及LD-NCPV的年度变化(β分别为0.082和0.086,p = 0.004和p = 0.006)独立相关。在每个斑块水平上,LDL-C未控制患者中CACs的增加与NCPV和LD-NCPV的年度变化独立相关(β分别为0.188和0.106,p < 0.001),而在LDL-C控制组中不相关(β分别为0.268和0.056,p = 0.085和0.08)。 结论:接受他汀类药物治疗的DM患者中CACs的增加表明斑块成分PVs的进展。从每个斑块的角度来看,在LDL-C未控制的患者中,随着CACs的增加,单个斑块的不稳定性可能增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/09454832c282/12933_2022_1556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/1094262dd640/12933_2022_1556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/2a6429be076c/12933_2022_1556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/09454832c282/12933_2022_1556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/1094262dd640/12933_2022_1556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/2a6429be076c/12933_2022_1556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d62b/9248151/09454832c282/12933_2022_1556_Fig3_HTML.jpg

相似文献

[1]
The effect of LDL-C status on the association between increased coronary artery calcium score and compositional plaque volume progression in statins-treated diabetic patients: evaluated using serial coronary CTAs.

Cardiovasc Diabetol. 2022-6-30

[2]
Improvement in LDL is associated with decrease in non-calcified plaque volume on coronary CTA as measured by automated quantitative software.

J Cardiovasc Comput Tomogr. 2018-5-7

[3]
Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study.

Eur Heart J Cardiovasc Imaging. 2019-11-1

[4]
Effect of long-term intensive cholesterol control on the plaque progression in elderly based on CTA cohort study.

Eur Radiol. 2022-7

[5]
Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression: A Serial CT Angiography Study.

JACC Cardiovasc Imaging. 2016-10-19

[6]
Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up.

J Thorac Imaging. 2022-9-1

[7]
Progression of coronary atherosclerotic plaque burden and relationship with adverse cardiovascular event in asymptomatic diabetic patients.

BMC Cardiovasc Disord. 2019-2-11

[8]
Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography.

Cardiovasc Diabetol. 2024-7-22

[9]
Serial coronary computed tomography angiography-verified coronary plaque progression: comparison of stented patients with or without diabetes.

Cardiovasc Diabetol. 2019-9-24

[10]
Aggravating effect of abnormal low-density protein cholesterol level on coronary atherosclerotic plaque in type 2 diabetes mellitus patients assessed by coronary computed tomography angiography.

Cardiovasc Diabetol. 2024-7-4

引用本文的文献

[1]
The role of coronary artery calcium scoring in the prediction of coronary artery disease based on non-contrast non-cardiac chest CT scans in airline pilots.

Front Cardiovasc Med. 2025-4-24

[2]
Bridging Prevention and Imaging: The Influence of Statins on CAC and CCTA Findings.

Curr Atheroscler Rep. 2025-4-8

[3]
Low-density lipoprotein cholesterol predicts coronary artery calcification events in patients with type 2 diabetes: a longitudinal study.

Diabetol Metab Syndr. 2025-2-12

[4]
The predictive value of coronary artery calcium score combined with traditional risk factors for obstructive coronary heart disease in young people.

BMC Cardiovasc Disord. 2024-9-10

[5]
Application of Quantitative Assessment of Coronary Atherosclerosis by Coronary Computed Tomographic Angiography.

Korean J Radiol. 2024-6

[6]
Deep learning-based coronary artery calcium score to predict coronary artery disease in type 2 diabetes mellitus.

Heliyon. 2024-3-10

[7]
Unsupervised machine learning based on clinical factors for the detection of coronary artery atherosclerosis in type 2 diabetes mellitus.

Cardiovasc Diabetol. 2022-11-28

[8]
Ethnicity should be included as a risk factor for coronary artery calcium score.

Cardiovasc Diabetol. 2022-8-8

本文引用的文献

[1]
Computed tomography angiography versus Agatston score for diagnosis of coronary artery disease in patients with stable chest pain: individual patient data meta-analysis of the international COME-CCT Consortium.

Eur Radiol. 2022-8

[2]
Effect of long-term intensive cholesterol control on the plaque progression in elderly based on CTA cohort study.

Eur Radiol. 2022-7

[3]
The adverse impact of coronary artery disease on left ventricle systolic and diastolic function in patients with type 2 diabetes mellitus: a 3.0T CMR study.

Cardiovasc Diabetol. 2022-2-22

[4]
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.

Circulation. 2022-3

[5]
Utilizing (serial) coronary computed tomography angiography (CCTA) to predict plaque progression and major adverse cardiac events (MACE): results, merits and challenges.

Eur Radiol. 2022-5

[6]
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.

Endocr Pract. 2020-10

[7]
Natural History of Adapted Leaman Score Assessing Coronary Artery Disease Progression by Computed Tomography Angiography: A 7-Year Follow-Up Report.

Cardiovasc Revasc Med. 2021-6

[8]
Impact of age on coronary artery plaque progression and clinical outcome: A PARADIGM substudy.

J Cardiovasc Comput Tomogr. 2021

[9]
Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study.

Cardiovasc Diabetol. 2020-9-25

[10]
Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry.

Cardiovasc Diabetol. 2020-7-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索